Gemina Laboratories Ltd (GLAB.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 01/31
(Values in thousands)
| 01-2025 | 01-2024 | 01-2023 | 01-2022 | |
| Cash Flows From Operating Activities | ||||
| Depreciation Amortization | 113 | 93 | 50 | 44 |
| Accounts receivable | 4 | 347 | -201 | -174 |
| Other Working Capital | 1,996 | 1,264 | 1,016 | 113 |
| Other Operating Activity | -3,414 | -4,948 | -5,375 | -3,855 |
| Operating Cash Flow | $-1,301 | $-3,244 | $-4,510 | $-3,872 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | 18 | -41 | -80 | -10 |
| Purchase Of Investment | N/A | 0 | -429 | N/A |
| Other Investing Activity | 0 | 0 | 4 | 18 |
| Investing Cash Flow | $18 | $-41 | $-505 | $8 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | 0 | 200 | N/A | N/A |
| Debt Issued | 910 | N/A | N/A | N/A |
| Debt Repayment | -117 | -90 | -63 | -68 |
| Common Stock Issued | 0 | 2,605 | 4,298 | 2,417 |
| Other Financing Activity | 490 | 489 | -293 | 1,788 |
| Financing Cash Flow | $1,282 | $3,203 | $3,941 | $4,138 |
| Beginning Cash Position | 1 | 83 | 1,156 | 882 |
| End Cash Position | 1 | 1 | 83 | 1,156 |
| Net Cash Flow | $0 | $-82 | $-1,073 | $274 |
| Free Cash Flow | ||||
| Operating Cash Flow | -1,301 | -3,244 | -4,510 | -3,872 |
| Capital Expenditure | N/A | -41 | -80 | -10 |
| Free Cash Flow | -1,301 | -3,285 | -4,589 | -3,882 |